JP2017500373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500373A5 JP2017500373A5 JP2016553259A JP2016553259A JP2017500373A5 JP 2017500373 A5 JP2017500373 A5 JP 2017500373A5 JP 2016553259 A JP2016553259 A JP 2016553259A JP 2016553259 A JP2016553259 A JP 2016553259A JP 2017500373 A5 JP2017500373 A5 JP 2017500373A5
- Authority
- JP
- Japan
- Prior art keywords
- sina
- myostatin
- molecule
- seq
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056852 Myostatin Proteins 0.000 claims description 68
- 102000004472 Myostatin Human genes 0.000 claims description 60
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 50
- 210000003205 muscle Anatomy 0.000 claims description 36
- 235000012000 cholesterol Nutrition 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 230000000692 anti-sense effect Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 15
- 108091081021 Sense strand Proteins 0.000 claims description 13
- 230000008685 targeting Effects 0.000 claims description 12
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 9
- 230000009368 gene silencing by RNA Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000007910 systemic administration Methods 0.000 claims description 7
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 208000017445 musculoskeletal system disease Diseases 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 244000144972 livestock Species 0.000 claims 1
- 244000089409 Erythrina poeppigiana Species 0.000 description 53
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 53
- 108020004459 Small interfering RNA Proteins 0.000 description 22
- 101100228739 Danio rerio mstnb gene Proteins 0.000 description 15
- 101150048453 MSTN gene Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 206010016256 fatigue Diseases 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 101150037241 CTNNB1 gene Proteins 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 102000000853 LDL receptors Human genes 0.000 description 5
- 108010001831 LDL receptors Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 101100448224 Mus musculus Mstn gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- -1 dimethoxytrityl Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- LFETXMWECUPHJA-UHFFFAOYSA-N methanamine;hydrate Chemical compound O.NC LFETXMWECUPHJA-UHFFFAOYSA-N 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000010966 qNMR Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000003854 type 2 muscle cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902358P | 2013-11-11 | 2013-11-11 | |
| US61/902,358 | 2013-11-11 | ||
| PCT/US2014/064837 WO2015070158A1 (en) | 2013-11-11 | 2014-11-10 | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036735A Division JP2020114821A (ja) | 2013-11-11 | 2020-03-04 | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500373A JP2017500373A (ja) | 2017-01-05 |
| JP2017500373A5 true JP2017500373A5 (https=) | 2017-12-21 |
| JP6672156B2 JP6672156B2 (ja) | 2020-03-25 |
Family
ID=51999542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553259A Active JP6672156B2 (ja) | 2013-11-11 | 2014-11-10 | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達 |
| JP2020036735A Pending JP2020114821A (ja) | 2013-11-11 | 2020-03-04 | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036735A Pending JP2020114821A (ja) | 2013-11-11 | 2020-03-04 | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10004814B2 (https=) |
| EP (1) | EP3068407A1 (https=) |
| JP (2) | JP6672156B2 (https=) |
| AU (2) | AU2014346457A1 (https=) |
| CA (1) | CA2929574A1 (https=) |
| WO (1) | WO2015070158A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| AU2017283546C1 (en) | 2016-06-13 | 2020-11-19 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| EP3516062A1 (en) | 2016-09-21 | 2019-07-31 | Alnylam Pharmaceuticals, Inc. | Myostatin irna compositions and methods of use thereof |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| ES2944357T3 (es) | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina |
| CN112930193A (zh) * | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| TW202039844A (zh) * | 2018-12-19 | 2020-11-01 | 美商阿尼拉製藥公司 | 類澱粉前驅蛋白（ＡＰＰ）ＲＮＡｉ劑組成物及其使用方法 |
| EP3995153A4 (en) * | 2019-06-26 | 2023-11-22 | KNC Laboratories Co., Ltd. | Nucleic acid drug suppressing production of myostatin gene mrna |
| JP2022553641A (ja) * | 2019-10-10 | 2022-12-26 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 疼痛の処置のためのアンチセンスオリゴヌクレオチド及びその使用 |
| CA3163283A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| AU2021340710A1 (en) * | 2020-09-11 | 2023-04-06 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
| US20240024492A1 (en) * | 2020-12-07 | 2024-01-25 | Olix Pharmaceuticals, Inc. | Nucleic acid molecule for induction of asymmetric rnai for inhibiting expression of ror-beta |
| EP4355878A4 (en) * | 2021-06-16 | 2025-04-09 | Empirico Inc. | TREATMENT OF MTRES1-RELATED DISEASES AND DISORDERS |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| IL321628A (en) | 2022-12-22 | 2025-08-01 | Scholar Rock Inc | Selective and potent inhibitory antibodies for myostatin activation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
| US20050266422A1 (en) | 2002-02-20 | 2005-12-01 | Sirna Therapeutics, Inc. | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides |
| US20090099117A1 (en) | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| CA2538208A1 (en) | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| US20090176725A1 (en) | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| JP5554231B2 (ja) * | 2007-06-13 | 2014-07-23 | コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション | トリの生産形質の改変 |
| CN103211099B (zh) * | 2013-04-09 | 2014-04-09 | 长沙学院 | 一种鳜鱼幼鱼肌肉生长促进剂 |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
-
2014
- 2014-11-10 US US15/035,950 patent/US10004814B2/en active Active
- 2014-11-10 CA CA2929574A patent/CA2929574A1/en not_active Abandoned
- 2014-11-10 AU AU2014346457A patent/AU2014346457A1/en not_active Abandoned
- 2014-11-10 EP EP14805434.9A patent/EP3068407A1/en not_active Withdrawn
- 2014-11-10 WO PCT/US2014/064837 patent/WO2015070158A1/en not_active Ceased
- 2014-11-10 JP JP2016553259A patent/JP6672156B2/ja active Active
-
2018
- 2018-05-31 US US15/994,450 patent/US10729787B2/en active Active
-
2020
- 2020-03-04 JP JP2020036735A patent/JP2020114821A/ja active Pending
- 2020-06-24 US US16/910,237 patent/US11529428B2/en active Active
-
2021
- 2021-01-21 AU AU2021200392A patent/AU2021200392A1/en not_active Abandoned
-
2022
- 2022-11-10 US US18/054,264 patent/US20230144623A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/027,971 patent/US20250312490A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500373A5 (https=) | ||
| Goyenvalle et al. | Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers | |
| Gait et al. | Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment | |
| Jearawiriyapaisarn et al. | Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice | |
| Betts et al. | Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment | |
| ES2561293T3 (es) | Inducción de la omisión de exón en células eucariotas | |
| DK2813570T3 (en) | Method for Effective Exon (44) Skipping in Duchenne Muscular Dystrophy and Similar Agents | |
| JP6126009B2 (ja) | α−シヌクレイン発現の調節 | |
| US20110130346A1 (en) | Peptide conjugates for delvery of biologically active compounds | |
| Monteith et al. | Synthetic oligonucleotides: the development of antisense therapeutics | |
| WO2020191212A1 (en) | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases | |
| EP3687577A1 (en) | Combination therapies for treating muscular dystrophy | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| McClorey et al. | Splicing intervention for Duchenne muscular dystrophy | |
| Hoffman et al. | Exon-skipping therapy: a roadblock, detour, or bump in the road? | |
| Muntoni et al. | 128th ENMC international workshop on ‘preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy’22–24 October 2004, Naarden, The Netherlands | |
| UA128819C2 (uk) | Модулятор експресії apol1 | |
| Almutiri et al. | Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons | |
| WO2019067979A1 (en) | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY | |
| AU2015301221A1 (en) | Inhibitors of MYH7B and uses thereof | |
| Koebis et al. | Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice | |
| Khorkova et al. | Nucleic acid–based therapeutics in orphan neurological disorders: Recent developments | |
| WO2016030899A1 (en) | Methods of treating amyotrophic lateral scleroses | |
| WO2019229133A1 (en) | Methods of treating or preventing an aging-related disease | |
| Wang et al. | Saponins as natural adjuvant for antisense morpholino oligonucleotides delivery in vitro and in mdx mice |